News
BHC
5.82
+1.39%
0.08
Weekly Report: what happened at BHC last week (0406-0410)?
Weekly Report · 3d ago
Bausch Health publishes 2025 annual report
Reuters · 6d ago
Bausch Health announces 2026 annual shareholder meeting via webcast
Reuters · 04/08 20:10
Bausch + Lomb wins FDA clearance for Bi-Blade+ vitrectomy cutter
Reuters · 04/08 11:00
TSX Pushes into Plus Column
Barchart · 04/07 15:35
Bausch + Lomb unveils new clinical data on cataract, dry eye portfolio at ASCRS meeting
Reuters · 04/06 11:01
Weekly Report: what happened at BHC last week (0330-0403)?
Weekly Report · 04/06 10:32
Bausch Health schedules first-quarter results release and conference call
Reuters · 03/31 21:07
Bausch + Lomb to report first-quarter financial results, host conference call and webcast
Reuters · 03/30 11:15
Weekly Report: what happened at BHC last week (0323-0327)?
Weekly Report · 03/30 10:32
Is the Options Market Predicting a Spike in Bausch Health Stock?
NASDAQ · 03/24 20:33
Tracking John Paulson's Paulson & Company Portfolio - Q4 2025 Update
Seeking Alpha · 03/24 12:08
AllianceBernstein Global High Income Fund Inc. Publishes Report; NAV $11.42
Reuters · 03/23 20:08
Bausch + Lomb reports 24-month U.S. ELIOS glaucoma trial results with 76% achieving ≥20% IOP reduction
Reuters · 03/23 11:01
Weekly Report: what happened at BHC last week (0316-0320)?
Weekly Report · 03/23 10:28
Weekly Report: what happened at BHC last week (0309-0313)?
Weekly Report · 03/16 10:27
Weekly Report: what happened at BHC last week (0302-0306)?
Weekly Report · 03/09 10:28
RSI Alert: Bausch Health Companies (BHC) Now Oversold
NASDAQ · 03/06 17:04
Cooper Companies raises 2026 profit forecast on demand for disposable contact lenses
Reuters · 03/05 22:52
Bausch + Lomb Director Thomas W. Ross Sr. Acquires Common Shares
Reuters · 03/04 21:19
More
Webull provides a variety of real-time BHC stock news. You can receive the latest news about Bausch Health Companies Inc through multiple platforms. This information may help you make smarter investment decisions.
About BHC
Bausch Health Companies Inc. is a global, diversified pharmaceutical company. The Salix segment includes sales in the U.S. of GI products. The International segment includes sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment includes global sales of Solta Medical aesthetic medical devices. The Diversified segment includes sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment includes global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products. Its drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients.